Please assess the completion status of the following clinical trial:

Trial Title: Microwave Ablation With MRI-Guided SBRT Boost in Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with imaging findings consistent with renal cell carcinoma~* Deemed medically inoperable per urology evaluation~* Tumor size \>4cm in largest dimension~* ECOG performance status of \<2~* Signed informed consent document(s)~* Patients with metastatic disease will not be excluded~Exclusion Criteria:~* Patients who fail MRI screening~* Pregnant or nursing women~* History of prior radiation therapy to the upper abdomen~* History of invasive cancer in the last 3 years (except for appropriately treated low-rist prostate cancer, treated non-melanoma/melanoma skin cancer, appropriately treated ductal carcinoma in situ or early stage invasive carcinoma of breast and appropriately treated in-situ/early stage cervical/endometrial cancer)~* Treatment with a non-approved or investigational drug within 28 days of study treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy & Microwave Ablation (Type: EXPERIMENTAL): 3+3 dose-escalation wherein three dose levels of stereotactic body radiation therapy (SBRT) would be evaluated:~1. Dose level I: 6 Gy x 5 fractions~2. Dose level II: 8 Gy x 5 fractions~3. Dose level III: 10 Gy x 5 fractions~Radiation treatments will be delivered two to three times a week, with five fractions completed over two weeks.~Four to six weeks after radiation treatment, patients will undergo repeat CT or MRI imaging to assess tumor response and suitability for microwave ablations.~Eight weeks after the conclusion of SBRT, patients will undergo microwave ablation (approximately 12 weeks after registration).

Based on this trial design, predict the completion outcome and termination type (if applicable).